

Table S2. Contribution of individual trials to the outcomes of interest.

Author	All-cause mortality	Cardiovascular mortality	Cardiovascular events	Acute myocardial infarction	Angina development / aggravation	Heart failure	Stroke	Hypertension development / aggravation	Thrombotic events	Dialysis vascular access thrombosis	Any serious adverse event	Progression to ESRD	Absolute GFR change*	Blood transfusion requirement
Canadian Erythropoietin Study Group ²⁸	0.0,2.5	—	—	—	—	—	—	7.5,31.6	—	2.5,18.4	—	—	—	2.5,2.6
Abraham ²⁹	—	—	—	—	—	—	—	37.2,58.3	—	—	—	—	—	—
Bahlmann ³⁰	3.0,3.2	1.5,1.6	—	—	1.6,6.1	—	0.0,1.5	7.6,23.8	—	6.1,7.9	—	—	—	9.4,60.9
Clyne ³¹	—	—	—	—	—	—	—	37.5,66.7	—	—	—	8.3,25.0	0.0	—
Muirhead ³²	6.7,21.1	—	—	—	—	—	—	40.0,57.9	53.3,78.9	17.7,23.1	—	—	—	—
Roth ³³	0.0,2.5	0.0,2.5	—	—	—	—	—	32.5,60.5	—	—	—	32.5,37.2	1.9,2.6	9.3,22.5
Nissenson ³⁴	1.4,2.6	—	—	—	—	—	—	20.0,54.9	—	—	20.3,26.9	—	—	—
Virost ³⁵	0.0,4.0	0.0,4.0	—	0.0,4.0	—	—	—	4.2,8.0	—	4.2,20.0	—	—	—	—
Besarab ³⁶	26.0,31.6	18.2,20.2	—	6.6,6.8	—	12.9,14.6	—	—	—	28.6,39.3	—	—	—	20.9,31.2
Kaufman ³⁷	7.9,10.3	—	—	—	—	—	—	—	—	—	—	—	—	6.5,8.9
Berns ³⁸	—	—	—	—	—	—	—	7.1,28.6	—	—	—	—	—	—
Conlon ³⁹	—	—	—	—	—	—	—	25.0,26.7	—	—	—	—	—	—
Foley ⁴⁰	4.1,5.5	—	13.7	—	—	—	—	—	—	8.2,13.7	—	—	—	—
Furuland ⁴¹	13.4,13.5	8.0,11.1	—	—	—	—	—	—	23.5,25.9	2.2,4.5	48.5,50.9	0.0,5.6	1.0,3.0	—
Levin ⁴²	1.3,4.1	0.0	—	0.0,1.4	5.1,5.4	4.1,6.4	—	—	—	0.0,1.3	1.4,6.4	10.8,14.1	4.5,6.6	—
Parfrey ⁴³	4.4,6.7	—	—	1.3,2.4	2.7,3.0	3.7,4.0	1.3,4.1	36.7,40.5	—	18.0,20.9	—	—	—	—
Provenzano ⁴⁴	0.8,2.3	—	—	—	—	—	—	6.2,7.3	1.5,3.8	—	—	—	—	—
Drüeke ⁴⁵	7.0,10.3	3.0,4.0	23.2,24.3	4.7,5.0	2.3,5.3	4.3,7.6	2.3,4.3	19.5,29.7	—	2.6,4.0	—	36.8,42.3	4.7,6.3	8.7,10.9
Rossert ⁴⁶	0.5,3.1	—	17.9,24.6	1.0	1.0,2.1	—	—	11.3,13.3	—	—	14.9,16.9	0.5,1.5	0.7,1.1	0.0
Singh ⁴⁷	5.0,7.3	—	13.5,17.5	2.5,2.8	—	6.6,9.0	1.7	—	17.4,18.4	—	48.5,54.8	—	—	—
Macdougall ⁴⁸	1.5,4.5	—	—	—	—	—	—	6.8,21.5	—	—	24.2,50.8	46.2,47.7	6.3,7.0	—
Ritz ⁴⁹	—	—	6.1,6.8	0.0,2.3	—	—	0.0,1.2	11.0,17.0	16.0,23.0	—	—	—	3.2,5.0	—
Bommer ⁵⁰	5.7,8.2	3.3,3.8	—	—	—	—	—	—	—	—	11.3,39.3	—	—	6.6,7.5
Chen ⁵¹	—	—	—	—	—	—	—	—	—	—	—	—	1.1,1.4	—
Spinowitz ⁵⁴	0.0,2.6	—	—	0.0,1.4	—	1.4,7.7	—	—	0.0,4.2	—	10.3,16.7	—	—	0.0,2.8
Cianciaruso ⁵²	0.0,2.2	0.0,2.2	—	—	—	—	0.0,2.2	—	—	—	—	8.2,8.7	1.2,1.5	—
Locatelli ⁵³	—	—	—	—	—	—	—	—	—	—	22.9,24.9	—	—	—
Pfeffer ⁸	19.5,20.5	12.3,12.9	29.7,31.4	6.2,6.4	—	10.2,11.3	2.6,5.0	22.1,24.5	8.4,10.9	0.1,0.2	60.4,61.6	16.3,16.8	—	14.8,24.5
Pergola ⁵⁶	0.0,4.8	0.0,2.4	—	0.0,0.8	—	—	0.8	4.8,11.4	1.6,2.4	—	15.4,22.4	1.6,2.5	—	0.8,7.3
Chazot ⁵⁵	3.9,10.4	—	—	—	—	—	—	—	—	—	—	—	—	—
Pergola ⁵⁷	2.8,4.2	0.9,2.8	—	—	—	—	—	12.1,13.2	2.8,4.7	—	22.4,26.4	1.9	—	3.7,6.5

Each cell contains the non-annualized actual event rate (%) range in the experimental and the placebo/control study arm during the follow-up period. In trials with more than two arms, only the arms with minimum and maximum event rate are depicted.

* This outcome represents the GFR change during the follow-up period, expressed in ml/min/1.73m²